SRC and chronic myelogenous leukemia, BCR-ABL1 positive: Only after treatment with the dual ABL/Src TK inhibitor dasatinib, a partial dephosphorylation of pLASP1-Y171, was observed (Figure 9A); phosphorylation of CRKL was completely blocked under these conditions, assuming different substrate specificities for the tyrosine kinases in CML.